
    
      This study is designed to be an open-label, longitudinal, uncontrolled study in a minimum of
      100 subjects with Fitzpatrick scale skin type of IV, V or VI at 10 or more U.S. centers who
      have elected to undergo NLF treatment with intradermal (deep dermal) injection of Elevess.
      Subjects will be followed for a minimum of 24 weeks with visit assessments at 2, 6, 12 and 24
      weeks after the last injection.

      Safety: Primary Safety Endpoint assessments will be: 1) keloid formation at the site of
      injection at 2, 6, 12 and 24 weeks, 2) pigmentation changes at the site of injection compared
      to adjacent skin at 2, 6, 12 and 24 weeks, and 3) overall adverse events. A subject diary
      will also be collected.

      Effectiveness: No formal effectiveness evaluation will be performed.
    
  